Cassian Yee, Eddie Goldenberg Research Chair of Canada in Next-Generation Translational T Cell Immunotherapies at University of Ottawa.

Cassian Yee

Cancer Immunotherapy

RESEARCH FIELD

Cancer Immunotherapy

T Cell Immunotherapy

Immunology

Education

The University of Winnipeg

B.S.

Studies

,

1982

University of Manitoba

M.D.

Doctor of Medicine

,

1986

Summary

Cassian Yee has been named the Eddie Goldenberg Research Chair of Canada in Next-Generation Translational T Cell Immunotherapies at University of Ottawa.

Cassian Yee is coming from the University of Texas MD Anderson Cancer Center, an American institution, making this a move from the United States to Canada.

The appointment is among the first 64 Eddie Goldenberg Research Chairs of Canada, announced on August 27, 2026 under the Government of Canada's Global Impact+ Research Talent Initiative.

Yee is a physician-scientist and internationally recognized leader in cellular therapy and tumor immunotherapy, focusing on T-cell therapies and T-cell receptor (TCR) engineering. In a landmark 2008 New England Journal of Medicine study, his team reported the first isolation and expansion of NY-ESO-1-specific CD4+ T-cell clones, and treatment of a patient with refractory metastatic melanoma produced a durable complete remission lasting 22 months.

His research spans antigen discovery, AI-guided TCR engineering, manufacturing and first-in-human trials. He has been principal investigator or co-investigator on more than 15 Investigational New Drug applications, leads or contributes to 14 early-phase clinical protocols, and has authored 144 peer-reviewed publications with more than 21,700 citations and an h-index of 69.

At the University of Ottawa, his program will build a Canadian-led pipeline of next-generation T cell therapies that use a patient's own immune cells to destroy cancer. It combines IPD-STAR, a technology that catalogues real tumour antigens, an AI-guided platform for designing precise TCRs, and his Endogenous T Cell (ETC) therapy, which creates durable T cells from a simple blood draw, supported by clinical-grade manufacturing and a national digital immunotherapy hub.

CURRENT AFFILIATION

University of Ottawa — Eddie Goldenberg Research Chair, Canada (anticipated July 2027)

Recruitment Program

Canada Global Impact+Research Talent Initiative